4:59 PM ET
Earnings Call
▶ Call
BioCardia Earnings Call: Key Takeaways
BioCardia is pivoting toward Japanese regulatory approval for Cardiamp and US de novo approval for Helix, while managing a tight $2.2 million cash runway into 2027.
- Call
- Nov 12, 2026, 4:30 PM ET